Leah Ben-Porat

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder
    Guido Dalbagni
    Department of Urology, Division of Epidemiology and Biostatistics, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 99:281-5. 2007
  2. ncbi request reprint Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy
    Michael J Zelefsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 55:956-63. 2003
  3. ncbi request reprint Mastectomy with immediate expander-implant reconstruction, adjuvant chemotherapy, and radiation for stage II-III breast cancer: treatment intervals and clinical outcomes
    Jean L Wright
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 70:43-50. 2008
  4. pmc Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade
    William R Jarnagin
    Departments of Surgery and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 236:397-406; discussion 406-7. 2002
  5. ncbi request reprint Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:5711-5. 2006
  6. ncbi request reprint Evaluation of postradiotherapy PSA patterns and correlation with 10-year disease free survival outcomes for prostate cancer
    Michael J Zelefsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 66:382-8. 2006
  7. ncbi request reprint Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer
    Vincent A Miller
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 22:1103-9. 2004
  8. ncbi request reprint When you look matters: the effect of assessment schedule on progression-free survival
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd St, 3rd Fl, New York, NY 10021, USA
    J Natl Cancer Inst 99:428-32. 2007
  9. ncbi request reprint Methodology for biologically-based treatment planning for combined low-dose-rate (permanent implant) and high-dose-rate (fractionated) treatment of prostate cancer
    Marco Zaider
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 61:702-13. 2005
  10. ncbi request reprint Patterns of treatment in older adults with primary central nervous system lymphoma
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 110:1338-44. 2007

Detail Information

Publications31

  1. ncbi request reprint Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder
    Guido Dalbagni
    Department of Urology, Division of Epidemiology and Biostatistics, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 99:281-5. 2007
    ....
  2. ncbi request reprint Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy
    Michael J Zelefsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 55:956-63. 2003
    ..We report the preliminary outcome of patients with localized prostate cancer treated with this approach...
  3. ncbi request reprint Mastectomy with immediate expander-implant reconstruction, adjuvant chemotherapy, and radiation for stage II-III breast cancer: treatment intervals and clinical outcomes
    Jean L Wright
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 70:43-50. 2008
    ....
  4. pmc Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade
    William R Jarnagin
    Departments of Surgery and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 236:397-406; discussion 406-7. 2002
    ..To assess the nature of changes in the field of hepatic resectional surgery and their impact on perioperative outcome...
  5. ncbi request reprint Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:5711-5. 2006
    ....
  6. ncbi request reprint Evaluation of postradiotherapy PSA patterns and correlation with 10-year disease free survival outcomes for prostate cancer
    Michael J Zelefsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 66:382-8. 2006
    ....
  7. ncbi request reprint Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer
    Vincent A Miller
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 22:1103-9. 2004
    ..Phase II trials suggested female sex and adenocarcinoma were associated with response. We undertook this analysis to identify additional clinical and pathologic features associated with sensitivity to gefitinib...
  8. ncbi request reprint When you look matters: the effect of assessment schedule on progression-free survival
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd St, 3rd Fl, New York, NY 10021, USA
    J Natl Cancer Inst 99:428-32. 2007
    ..The decision to use PFS as a primary endpoint should be made carefully when designing clinical trials, and investigators focused on a particular disease should develop consensus standards and strive for consistent surveillance intervals...
  9. ncbi request reprint Methodology for biologically-based treatment planning for combined low-dose-rate (permanent implant) and high-dose-rate (fractionated) treatment of prostate cancer
    Marco Zaider
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 61:702-13. 2005
    ....
  10. ncbi request reprint Patterns of treatment in older adults with primary central nervous system lymphoma
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 110:1338-44. 2007
    ..The objective of the current study was to identify factors associated with the receipt and type of treatment in a population-based cohort of older PCNSL patients...
  11. ncbi request reprint Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder
    Guido Dalbagni
    Department of Urology, Division of Epidemiology and Biostatistics, The Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:2729-34. 2006
    ..The aim of this phase II study was to determine the efficacy of gemcitabine administered as an intravesical agent in patients with bacille Calmette-Guérin (BCG) -refractory transitional cell carcinoma of the bladder...
  12. ncbi request reprint Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer
    Michael J Zelefsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 23:826-31. 2005
    ..To identify predictors of distant metastases (DM) among patients who develop an isolated prostate-specific antigen (PSA) relapse after definitive external-beam radiotherapy for clinically localized prostate cancer...
  13. ncbi request reprint Clinicopathological features of and risk factors for multiple primary melanomas
    Cristina R Ferrone
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    JAMA 294:1647-54. 2005
    ..The incidence of multiple primary melanomas ranges from 1.3% to 8.0% in large retrospective reviews; however, the impact of certain risk factors is not understood...
  14. ncbi request reprint Estimates of stage-specific survival are altered by changes in the 2002 American Joint Committee on Cancer staging system for melanoma
    Leah Ben-Porat
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 106:163-71. 2006
    ....
  15. pmc Fluorescence-assisted cytological testing (FACT): Ex Vivo viral method for enhancing detection of rare cancer cells in body fluids
    Prasad S Adusumilli
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Mol Med 17:628-34. 2011
    ..This method was demonstrated to be a reliable screening tool for human cancer cells in a suspension of normal murine cells as well as clinical specimens of malignant pleural effusions...
  16. pmc Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma
    William R Jarnagin
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 241:703-12; discussion 712-4. 2005
    ..The current study compares outcome after resection of papillary hilar cholangiocarcinoma to that of the more common nodular-sclerosing subtype...
  17. ncbi request reprint Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:2466-72. 2005
    ..The objective of this study was to examine time trends in overall survival and disease-specific mortality in a population-based cohort of patients with PCNSL...
  18. ncbi request reprint Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma
    William G Hawkins
    Department of Surgery, Washington University, St Louis, Missouri 63110, USA
    Ann Surg Oncol 12:207-13. 2005
    ..Pathologic heterogeneity within DM may account for the controversy regarding the clinical presentation and prognosis of DM compared with conventional melanoma (CM)...
  19. ncbi request reprint Operative salvage for locoregional recurrent colon cancer after curative resection: an analysis of 100 cases
    Wilbur B Bowne
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Dis Colon Rectum 48:897-909. 2005
    ..This investigation was undertaken to review our experience with surgical resection for patients with locoregional recurrence colon cancer, determine predictors of respectability, and define prognostic factors associated with survival...
  20. ncbi request reprint Sun exposure and mortality from melanoma
    Marianne Berwick
    University of New Mexico, Department of Internal Medicine, New Mexico Cancer Research Facility, MSC08 4630, Room 103A, 1 University of New Mexico, Albuquerque, NM 87131, USA
    J Natl Cancer Inst 97:195-9. 2005
    ..We therefore evaluated the association between measures of skin screening and death from cutaneous melanoma...
  21. ncbi request reprint Practical management of patients with non-small-cell lung cancer treated with gefitinib
    Neelam T Shah
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 23:165-74. 2005
    ..Many of the principles of management relevant to gefitinib are distinct from those with conventional cytotoxic drugs. To meet this need, we present practical guidelines on the use of gefitinib in patients with non-small-cell lung cancer...
  22. pmc Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases
    David A Kooby
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg 237:860-9; discussion 869-70. 2003
    ..To determine if transfusion affected perioperative and long-term outcome in patients undergoing liver resection for metastatic colorectal cancer...
  23. ncbi request reprint Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer
    William G Hawkins
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 11:310-5. 2004
    ..In patients with gallbladder cancer, jaundice suggests tumor involvement of the porta hepatis. This study reports on the prevalence, etiology, and clinical significance of jaundice in patients with gallbladder cancer...
  24. ncbi request reprint Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases
    Peter J Allen
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY10021, USA
    J Am Coll Surg 201:57-65. 2005
    ..Successful use of a hepatic arterial infusion pump requires a low technical complication rate. We evaluated the complications and longterm durability of these devices at our institution...
  25. pmc Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer
    Marianne Berwick
    Cancer Research and Treatment Center Internal Medicine, University of New Mexico, Albuquerque, New Mexico, USA
    Cancer Res 67:9591-6. 2007
    ..4; 95% CI, 1.1-5.2). Overall, there was no increased risk for cancer among FA heterozygotes in this study of Fanconi relatives, although there is some evidence that FANCC mutations are possibly breast cancer susceptibility alleles...
  26. ncbi request reprint Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma
    Gary A Ulaner
    Medical Service, Veterans Administration Palo Alto Health Care System, and Department of Medicine, Stanford University, Palo Alto, California 94304, USA
    Cancer Res 63:1759-63. 2003
    ..Finally, we note that OS cases with a TA-/ALT+ phenotype seem to be as clinically aggressive as TA+ cases in terms of stage and clinical outcome...
  27. ncbi request reprint Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer
    Monica Prasad
    Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 93:223-8. 2004
    ..We report overall costs and treatment outcomes associated with topotecan or gemcitabine administration in platinum- and paclitaxel-resistant EOC patients...
  28. ncbi request reprint Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia
    John E Wagner
    Division of Pediatric Hematology, Oncology, and Blood Marrow Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA
    Blood 103:3226-9. 2004
    ..Our results suggest that BRCA2 testing should be considered in all patients with FA in whom the complementation group cannot be defined or in whom leukemia is diagnosed at or before 5 years of age...
  29. ncbi request reprint Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma
    Bhavana Pothuri
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 96:330-4. 2005
    ..To analyze the feasibility of using percutaneous endoscopic gastrostomy (PEG) tube placement in ovarian cancer patients with malignant bowel obstruction and to analyze the outcome of these patients...
  30. ncbi request reprint Optimal abdominal incision for partial hepatectomy: increased late complications with Mercedes-type incisions compared to extended right subcostal incisions
    Michael D'Angelica
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    World J Surg 30:410-8. 2006
    ..The optimal abdominal incision for partial hepatectomy has not been established...
  31. pmc Assessing the quality of reports of randomized trials in pediatric complementary and alternative medicine
    David Moher
    Thomas C Chalmers Centre for Systematic Reviews, Children s Hospital of Eastern Ontario Research Institute, Canada
    BMC Pediatr 2:2. 2002
    ..To evaluate the quality of reports of complementary and alternative medicine (CAM) randomized controlled trials (RCTs) in the pediatric population. We also examined whether there was a change in the quality of reporting over time...